Clinical Trial Update: Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers [Phase 1]

View source ↗

Summary

Phase 1 safety and bioimaging trial of DS-8895a in patients with advanced EphA2-positive cancers completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epha2-positive Cancer
• Malignant Solid Tumor

Drugs mentioned

• DS-8895a (DS-8895a)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Malignant Solid Tumor, Metastatic EphA2 Positive Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-03-01